BioHealth News
Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy
ROCKVILLE, Md., May 23, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the…
Read More
Activation Capital Introduces ‘Frontier BioHealth’ to Catalyze Life Science Startups
RICHMOND, Va., May 23, 2024 /PRNewswire/ -- Activation Capital announces the launch of Frontier BioHealth, an educational and support program designed to provide highly specialized training,…
Read More
ARPA-H’s NITRO selects teams to lead breakthroughs in reversing OA
Program performer teams to develop innovative ways for joints to heal themselves The Advanced Research Projects Agency for Health (ARPA-H), an agency within the…
Read More
Rockville’s Theriva™ Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Metastatic Pancreatic Cancer
ROCKVILLE, Md., May 23, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and…
Read More
Nona Biosciences Announces Global License and Option Agreement with AstraZeneca for Monoclonal Antibody to be Developed into Novel Tumor Targeted Therapies
Nona Biosciences, a global biotechnology company providing a total solution from “Idea to IND” (I to ITM), ranging from target validation and antibody discovery…
Read More
Frederick’s Theradaptive Secures $1M in Funding from Maryland Stem Cell Research Fund for Human Clinical Trials
FREDERICK, Md., May 22, 2024 /PRNewswire/ -- Theradaptive, Inc., a regenerative medicine company developing targeted therapeutics, announced today it has been awarded funding from the Maryland…
Read More
PQE Group US Earns Great Place to Work Certification™
Rockville, MD, May 22, 2024. PQE Group is proud to announce that, for the third consecutive year, its US subsidiary has been Certified™ by…
Read More
MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development
Legend Biotech obtains license to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its non-viral engineered pipeline portfolio across a variety of…
Read More
Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia Gravis
GAITHERSBURG, Md., May 22, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for…
Read More
Welldoc Certified as a Great Place to Work® for Third Year in a Row
COLUMBIA, Md., May 21, 2024 — Welldoc®, a leading digital health company specializing in AI-driven cardiometabolic health, announced today that it was Certified™ by Great Place…
Read More
Save the Dates: 2024 BioHealth Capital Region Week Registration Coming Soon
Looking forward to the Autumn of 2024, the BioHealth Capital Region is gearing up for three major events, September 17th, 18th, and 19th, 2024,…
Read More
Gaithersburg’s Amplexd Therapeutics, Innovating to Revolutionize the Future of Non-Invasive HPV-induced Cervical Intraepithelial Neoplasia (CIN) Treatments for the Prevention of Cervical Cancer: Developed by Women for Women
GAITHERSBURG, MD, May 20, 2024 (GLOBE NEWSWIRE) -- Amplexd Therapeutics, Inc. (“Amplexd” or the “Company”), a clinical stage patient-scientist-led biotech company specializing in accessible…
Read More
Baltimore Fishbowl: MCB Real Estate announces plans for a mixed-use development in Montgomery County that will have a focus on the life sciences and biohealth
MCB Real Estate, the developer of Harborplace in Baltimore, announced on Thursday that it will lead the development of VIVA White Oak, a mixed…
Read More
Vanda Pharmaceuticals Reports Positive Results from a Second Phase III Study of Tradipitant in Motion Sickness
WASHINGTON, May 15, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the results from its second Phase III study of tradipitant in motion sickness,…
Read More
Sands Capital’s Pulse Fund III Secures $555M Close
The Life Sciences Pulse strategy partners with private companies helping transform how diseases are defined, diagnosed, and treated. Sands Capital is pleased to announce…
Read More